RightFit
Not yet recruitingPhase 4

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
40 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

The primary objective of this study is to determine if the addition of Rocklatan post-Hydrus will provide additional intraocular pressure lowering.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Official eligibility criteria

Inclusion Criteria: * Age 40 years and older * Subjects who have mild to moderate Open Angle Glaucoma (OAG) * Subjects who have undergone uncomplicated cataract surgery and Hydrus microstent implantation \> 3 months prior to screening and within the last 2 years * Post-Hydrus subjects on 0-2 ocular hypotensive medication classes who can safely washout (if on ocular hypotensive medications) * Unmedicated or washed out IOP range between 16-26 mmHg Exclusion Criteria: * History of intraocular surgery except for uneventful refractive surgery or uncomplicated cataract surgery and hydrus microstent implantation * Prior Selective Laser Trabeculoplasty (SLT) within 18 months of surgery * Secondary glaucoma excluding pseudoexfoliation and pigmentary dispersion syndrome * Severe Open Angle Glaucoma * Narrow angles, other angle abnormalities or angle closure glaucoma * Allergy or intolerance to Rocklatan * History of corneal edema, or corneal disease or dystrophy * Current or history of intra-ocular infection or inflammation * History of retinal diseases that could affect diagnostic testing * Anticipated use of intra-ocular or topical steroids not associated with the study protocol * Pregnant, breastfeeding or planning to become pregnant during the study * Any condition in the opinion in the investigator that would potentially confound the results of the study

Study sites (1)

NV